Public Release: 

Study targets stroke prevention in children with sickle cell anemia

St. Jude Children's Research Hospital scientists awarded federal grant to lead comparison of treatment options

St. Jude Children's Research Hospital

St. Jude Children's Research Hospital investigators were recently awarded a $23 million federal grant to launch a national study of the drug hydroxyurea to prevent first strokes in children and adolescents with sickle cell anemia (SCA).

The effort will be the fifth at St. Jude involving hydroxyurea to treat children with SCA. The focus will be on SCA patients who have not suffered strokes but have been identified as high risk for the complication by transcranial Doppler ultrasound (TCD) screening. The five-year study is expected to include a total of 26 medical centers and about 140 patients.

"Our goal with this study is to prevent brain complications in children with sickle cell disease," explained Russell Ware, M.D., Ph.D., principal investigator for the study, which is funded by the National Heart, Lung, and Blood Institute. Ware chairs the St. Jude Department of Hematology and holds the Lemuel Diggs Endowed Chair in Sickle Cell Disease.

SCA is an inherited blood disorder. In the U.S., it is diagnosed most frequently in African American individuals. The sickled red blood cells they produce can disrupt circulation and cause pain, strokes and other debilitating and sometimes deadly complications.

The new study is called TWiTCH, short for TCD With Transfusions Changing to Hydroxyurea. Patients will be randomly assigned to either continue a standard therapy of monthly blood transfusions and chelation to remove the resulting iron buildup or to receive a daily dose of hydroxyurea and monthly phlebotomy to remove excess iron. The goal is to compare the two treatments, including their ability to prevent a first stroke.

###

St. Jude Children's Research Hospital

St. Jude Children's Research Hospital is internationally recognized for its pioneering work in finding cures and saving children with cancer and other catastrophic diseases. Founded by late entertainer Danny Thomas and based in Memphis, Tenn., St. Jude freely shares its discoveries with scientific and medical communities around the world. No family ever pays for treatments not covered by insurance, and families without insurance are never asked to pay. St. Jude is financially supported by ALSAC, its fundraising organization. For more information, please visit www.stjude.org.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.